Citations (43)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Alexandro Guterres, Mayla Abrahim & Patrícia Cristina da Costa Neves. (2023) The role of immune subtyping in glioma mRNA vaccine development. Immunotherapy 15:13, pages 1057-1072.
Read now
Read now
Yung-Sung Yeh, Hsiang-Lin Tsai, Po-Jung Chen, Yen-Cheng Chen, Wei-Chih Su, Tsung-Kun Chang, Ching-Wen Huang & Jaw-Yuan Wang. (2023) Identifying and clinically validating biomarkers for immunotherapy in colorectal cancer. Expert Review of Molecular Diagnostics 23:3, pages 231-241.
Read now
Read now
Articles from other publishers (41)
Klaudia Kiel, Sylwia Katarzyna Król, Agnieszka Bronisz & Jakub Godlewski. (2024) MiR-128-3p – a gray eminence of the human central nervous system. Molecular Therapy - Nucleic Acids 35:1, pages 102141.
Crossref
Crossref
Jiin Choi & Hee Jin Cho. (2024) Comprehensive Transcriptomic Profiling of Diverse Brain Tumor Types Uncovers Complex Structures of the Brain Tumor Microenvironment. Biomedicines 12:3, pages 506.
Crossref
Crossref
A. Romanishin, A. Vasilev, E. Khasanshin, A. Evtekhov, E. Pusynin, K. Rubina, V. Kakotkin, M. Agapov & E. Semina. (2024) Oncolytic viral therapy for gliomas: Advances in the mechanisms and approaches to delivery. Virology, pages 110033.
Crossref
Crossref
Herui Wang, Rogelio Medina, Juan Ye, Yaping Zhang, Samik Chakraborty, Alex Valenzuela, Ondrej Uher, Katerina Hadrava Vanova, Mitchell Sun, Xueyu Sang, Deric M. Park, Jan Zenka, Mark R. Gilbert, Karel Pacak & Zhengping Zhuang. (2024) rWTC‐MBTA Vaccine Induces Potent Adaptive Immune Responses Against Glioblastomas via Dynamic Activation of Dendritic Cells. Advanced Science.
Crossref
Crossref
Somaya A. Abdel-Rahman & Moustafa Gabr. (2024) Small Molecule Immunomodulators as Next-Generation Therapeutics for Glioblastoma. Cancers 16:2, pages 435.
Crossref
Crossref
Amin Kamrani, Hadi Nasiri, Ali Hassanzadeh, Javad Ahmadian Heris, Reza Mohammadinasab, Shahram Sadeghvand, Mohammadreza Sadeghi, Zahra Valedkarimi, Ramin Hosseinzadeh, Navid Shomali & Morteza Akbari. (2024) New immunotherapy approaches for colorectal cancer: focusing on CAR-T cell, BiTE, and oncolytic viruses. Cell Communication and Signaling 22:1.
Crossref
Crossref
Guillaume Mestrallet. (2024) Predicting Immunotherapy Outcomes in Glioblastoma Patients through Machine Learning. Cancers 16:2, pages 408.
Crossref
Crossref
Vanajothi Ramar, Shanchun Guo, BreAnna Hudson & Mingli Liu. (2023) Progress in Glioma Stem Cell Research. Cancers 16:1, pages 102.
Crossref
Crossref
Аleksandra Kosianova, Oleg Pak & Igor Bryukhovetskiy. (2023) Regulation of cancer stem cells and immunotherapy of glioblastoma (Review). Biomedical Reports 20:2.
Crossref
Crossref
Travis Yui Hei Chan, Jenny Sum Yee Wong, Karrie Mei-Yee Kiang, Cherry Won Yuet Sun & Gilberto Ka-Kit Leung. (2023) The duality of CXCR3 in glioblastoma: unveiling autocrine and paracrine mechanisms for novel therapeutic approaches. Cell Death & Disease 14:12.
Crossref
Crossref
Jiaying Zheng, Lingxiao Wang, Shunyi Zhao, Wenjing Zhang, Yuzhou Chang, Dale B Bosco, Tao Huang, Aastha Dheer, Shan Gao, Shengze Xu, Katayoun Ayasoufi, Rawan Al-Kharboosh, Fangfang Qi, Manling Xie, Aaron J Johnson, Haidong Dong, Alfredo Quiñones-Hinojosa & Long-Jun Wu. (2023) TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas. Neuro-Oncology.
Crossref
Crossref
Jun Takei, Yuko Kamata, Toshihide Tanaka, Nei Fukasawa, Kazutaka Gomisawa, Mari Satake, Ryosuke Mori, Yohei Yamamoto, Tomoya Suzuki, Ayaka Oda, Mutsunori Murahashi, Takahiro Fukuda, Masayuki Shimoda, Yuichi Murayama & Yasuharu Akasaki. (2023) Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma. Cancer Immunology, Immunotherapy 72:10, pages 3175-3189.
Crossref
Crossref
Xudong Liu, Zihui Zhao, Wufei Dai, Kuo Liao, Qi Sun, Dongjiang Chen, Xingxin Pan, Lishuang Feng, Ying Ding & Shiyou Wei. (2023) The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma. Cancers 15:17, pages 4308.
Crossref
Crossref
Zhen Zhao, Baoping Zheng, Jianglin Zheng, Yi Zhang, Cheng Jiang, Chuansheng Nie, Xiaobing Jiang, Dongxiao Yao & Hongyang Zhao. (2023) Integrative Analysis of Inflammatory Response-Related Gene for Predicting Prognosis and Immunotherapy in Glioma. Journal of Molecular Neuroscience 73:7-8, pages 608-627.
Crossref
Crossref
Aetsam Bin Masood, Sajida Batool, Sajid Nazir Bhatti, Asad Ali, Marian Valko, Klaudia Jomova & Kamil Kuca. (2023) Plasma PD-L1 as a biomarker in the clinical management of glioblastoma multiforme—a retrospective cohort study. Frontiers in Immunology 14.
Crossref
Crossref
Guojun Yao, Ling Deng, Xinquan Long, Yufan Zhou & Xiang Zhou. (2023) An integrated bioinformatic investigation of focal adhesion-related genes in glioma followed by preliminary validation of COL1A2 in tumorigenesis. Aging 15:13, pages 6225-6254.
Crossref
Crossref
Tao Jiang, Xianwei Wang, Jiaming Huang & Dong Chen. (2023) CDC42—A promising immune-related target in glioma. Frontiers in Neuroscience 17.
Crossref
Crossref
Ruizhi Tian, Zhihong Liu, Youming Chen, Xun Wang, Hancheng Zhou & Shousen Wang. (2023) Mechanism of polyethylene glycol and polyethylenimine combined with superparamagnetic nanoparticles in treating the brain glioma. Materials Express 13:7, pages 1138-1145.
Crossref
Crossref
Samuel Luca Rocha Pinheiro, Fabian Fellipe Bueno Lemos, Hanna Santos Marques, Marcel Silva Luz, Luís Guilherme de Oliveira Silva, Clara Faria Souza Mendes dos Santos, Karolaine da Costa Evangelista, Mariana Santos Calmon, Matheus Sande Loureiro & Fabrício Freire de Melo. (2023) Immunotherapy in glioblastoma treatment: Current state and future prospects. World Journal of Clinical Oncology 14:4, pages 138-159.
Crossref
Crossref
Hai Zou, Xiao‐Zhou Mou & Biao Zhu. (2022) Combining of Oncolytic Virotherapy and Other Immunotherapeutic Approaches in Cancer: A Powerful Functionalization Tactic. Global Challenges 7:1.
Crossref
Crossref
Rui Sun & Albert H. Kim. (2022) The multifaceted mechanisms of malignant glioblastoma progression and clinical implications. Cancer and Metastasis Reviews 41:4, pages 871-898.
Crossref
Crossref
Thi-Anh-Thuy Tran, Young-Hee Kim, Ga-Eun Kim, Shin Jung, In-Young Kim, Kyung-Sub Moon, Young-Jin Kim, Tae-Kyu Lee, Hyosuk Yun, Je-Jung Lee, Hyun-Ju Lee, Chul Won Lee & Tae-Young Jung. (2022) The long multi-epitope peptide vaccine combined with adjuvants improved the therapeutic effects in a glioblastoma mouse model. Frontiers in Immunology 13.
Crossref
Crossref
Hongxiang Jiang, Zhiqiang Sun, Fei Li & Qianxue Chen. (2022) Prognostic value of γ‐aminobutyric acidergic synapse-associated signature for lower-grade gliomas. Frontiers in Immunology 13.
Crossref
Crossref
Mingzhi Han, Yanfei Sun, Wenbo Zhao, Guo Xiang, Xu Wang, Zheng Jiang, Zhiwei Xue & Wei Zhou. (2022) Comprehensive characterization of TNFSF14/LIGHT with implications in prognosis and immunotherapy of human gliomas. Frontiers in Immunology 13.
Crossref
Crossref
Ahmad Bakur Mahmoud, Reham Ajina, Sarah Aref, Manar Darwish, May Alsayb, Mustafa Taher, Shaker A. AlSharif, Anwar M. Hashem & Almohanad A. Alkayyal. (2022) Advances in immunotherapy for glioblastoma multiforme. Frontiers in Immunology 13.
Crossref
Crossref
Hongxiang Jiang, Fei Li, Linzhi Cai & Qianxue Chen. (2022) Role of the TSPO–NOX4 axis in angiogenesis in glioblastoma. Frontiers in Pharmacology 13.
Crossref
Crossref
Ellen Poot, Ander Maguregui, Valerie G. Brunton, Dirk Sieger & Alison N. Hulme. (2022) Targeting glioblastoma through nano- and micro-particle-mediated immune modulation. Bioorganic & Medicinal Chemistry 72, pages 116913.
Crossref
Crossref
Jian Hou, Xiangyang Wen, Zhenquan Lu, Guoqing Wu, Guang Yang, Cheng Tang, Genyi Qu & Yong Xu. (2022) A novel T-cell proliferation-associated regulator signature pre-operatively predicted the prognostic of bladder cancer. Frontiers in Immunology 13.
Crossref
Crossref
Andrea Franson, Brandon L. McClellan, Maria Luisa Varela, Andrea Comba, Mohammad Faisal Syed, Kaushik Banerjee, Ziwen Zhu, Nazareno Gonzalez, Marianela Candolfi, Pedro Lowenstein & Maria Graciela Castro. (2022) Development of immunotherapy for high-grade gliomas: Overcoming the immunosuppressive tumor microenvironment. Frontiers in Medicine 9.
Crossref
Crossref
Heena Sareen, Yafeng Ma, Therese M. Becker, Tara L. Roberts, Paul de Souza & Branka Powter. (2022) Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences 23:16, pages 8835.
Crossref
Crossref
Juliana B. Vilar, Markus Christmann & Maja T. Tomicic. (2022) Alterations in Molecular Profiles Affecting Glioblastoma Resistance to Radiochemotherapy: Where Does the Good Go?. Cancers 14:10, pages 2416.
Crossref
Crossref
Mariana Afonso & Maria Alexandra Brito. (2022) Therapeutic Options in Neuro-Oncology. International Journal of Molecular Sciences 23:10, pages 5351.
Crossref
Crossref
Beata Pająk. (2022) Looking for the Holy Grail—Drug Candidates for Glioblastoma Multiforme Chemotherapy. Biomedicines 10:5, pages 1001.
Crossref
Crossref
Ying Bi, Zeng-Hong Wu & Fei Cao. (2022) Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma. BMC Cancer 22:1.
Crossref
Crossref
Yuan Jiang, Qiankun Ji, Xiaoyan Long, Peng Wang, Zewei Tu, Xian Zhang, Xingen Zhu, Kai Huang & Jingying Li. (2022) CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma. Frontiers in Immunology 13.
Crossref
Crossref
Ming Ji, Dongjie Wang, Songwen Lin, Chunyang Wang, Ling Li, Zhihui Zhang, Jing Jin, Deyu Wu, Yi Dong, Heng Xu, Duo Lu & Xiaoguang Chen. (2022) A novel PI3K inhibitor XH30 suppresses orthotopic glioblastoma and brain metastasis in mice models. Acta Pharmaceutica Sinica B 12:2, pages 774-786.
Crossref
Crossref
Pavel V. Ershov, Yuri V. Mezentsev & Alexis S. Ivanov. (2022) Interfacial Peptides as Affinity Modulating Agents of Protein-Protein Interactions. Biomolecules 12:1, pages 106.
Crossref
Crossref
Xingwang Zhou, Wenyan Li, Jie Yang, Xiaolan Qi, Yimin Chen, Hua Yang & Liangzhao Chu. (2021) Tertiary lymphoid structure stratifies glioma into three distinct tumor subtypes. Aging 13:24, pages 26063-26094.
Crossref
Crossref
Noha Attia, Mohamed Mashal, Sudhakar Pemminati, Adekunle Omole, Carolyn Edmondson, Will Jones, Priyanka Priyadarshini, Temoria Mughal, Pauline Aziz, Blesing Zenick, Ambar Perez & Morgan Lacken. (2021) Cell-Based Therapy for the Treatment of Glioblastoma: An Update from Preclinical to Clinical Studies. Cells 11:1, pages 116.
Crossref
Crossref
Peng Wang, Jingying Li, Miaojing Wu, Minghua Ye, Kai Huang & Xingen Zhu. (2021) Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients. Frontiers in Immunology 12.
Crossref
Crossref
Zihao Wang, Yaning Wang, Tianrui Yang, Hao Xing, Yuekun Wang, Lu Gao, Xiaopeng Guo, Bing Xing, Yu Wang & Wenbin Ma. (2021) Machine learning revealed stemness features and a novel stemness-based classification with appealing implications in discriminating the prognosis, immunotherapy and temozolomide responses of 906 glioblastoma patients. Briefings in Bioinformatics 22:5.
Crossref
Crossref